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Summary Docetaxel, a new semisynthetic taxoid that has demonstrated promising activity as an antineoplastic agent, was administered in
combination with cisplatin to 63 patients in a dose-escalating study. As both drugs were known to be potentially neurotoxic, peripheral
neurotoxicity was prospectively assessed in detail. Neuropathy was evaluated by clinical sum-score for signs and symptoms and by
measurement of the vibration perception threshold (VPT). The severity of neuropathy was graded according to the National Cancer Institute's
'Common Toxicity Criteria'. The docetaxel - cisplatin combination chemotherapy induced a predominantly sensory neuropathy in 29 (53%)
out of 55 evaluable patients. At cumulative doses of both cisplatin and docetaxel above 200 mg m-2, 26 (74%) out of 35 patients developed
a neuropathy which was mild in 15, moderate in ten and severe in one patient. Significant correlations were present between both
the cumulative dose of docetaxel and cisplatin and the post-treatment sum-score of neuropathy (P < 0.01) as well as the post-treatment VPT
(P < 0.01). The neurotoxic effects of this combination were more severe than either cisplatin or docetaxel as single agent at similar doses.
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Docetaxel (Taxotere) is a new semisynthetic taxoid that has
demonstrated substantial clinical activity against a wide variety of
solid tumours (Pazdur et al, 1993; Aamdal et al, 1994; Fossella et
al, 1994; Francis et al, 1994a; Francis et al, 1994b; Smyth et al,
1994; Chevallier et al, 1995). Docetaxel inhibits tubulin depoly-
merization and promotes microtubule assembly, resulting in
dysfunctional microtubules (Pazdur et al, 1993).
In view of their partly non-overlapping side-effects and their
activities in awide range oftumourtypes,developing combination
chemotherapy regimens, including both taxoids and platins, is
of major interest (Rowinsky et al, 1991; Rowinsky et al, 1993;
Chaudhry et al, 1994). An important dose-dependent side-effect of
cisplatin is the development of peripheral neuropathy, mainly
affecting thick-fibre-mediated sensory qualities (Thompson et al,
1984; Roelofs et al, 1984; Gerritsen van der Hoop et al, 1990a;
Vecht et al, 1991; Hilkens et al, 1994). Neuropathy has also been
reported as a dose-dependent side-effect of treatment with pacli-
taxel (Taxol) (Lipton et al, 1989; Gerven et al, 1994). As expected,
trials on combination chemotherapy of cisplatin and paclitaxel
found a high incidence of peripheral neuropathy (Rowinsky et al,
1991; Rowinsky et al, 1993; Chaudhry et al, 1994).
Peripheral neurotoxicity has been reported as a frequent, but
usually mild side-effect ofdocetaxel in several phase I and phase II
studies (Bissett et al, 1993; Extra et al, 1993; Aamdal et al, 1994;
Fossella et al, 1994; Francis et al, 1994a; Francis et al, 1994b;
Smyth et al, 1994; Chevallier et al, 1995; Hilkens et al, 1996; New
et al, 1996). The neurotoxic effects of docetaxel in combination
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chemotherapy with cisplatin are unknown. In our institution, a
phase I trial on the combination of docetaxel and cisplatin in
metastatic or locally advanced solid tumours was conducted
(Pronk et al, 1996). In order to study the neurotoxicity of this
combination chemotherapy, weprospectively evaluated allpatients
participating in this trial by detailed neurological examinations.
PATIENTS AND METHODS
All participating patients had a metastatic or locally advanced
solid tumour for which no other appropriate anti-tumour therapy
was available. Other inclusion criteria included age 18-75 years,
WHO performance status 0-2, no prior treatment with platinum
derivates ortaxoids,normal organ functions, a life expectancy of3
months or more and written informed consent. Patients with symp-
tomatic peripheral neuropathy grade 1 or more according to the
'National Cancer Institute (NCI) criteria' (Table 1) and patients
with brain or leptomeningeal metastases were excluded.
Chemotherapy was administered in 3-weekly regimens.
Docetaxel, supplied by Rh8ne-Poulenc Rorer, was given as a
1-h infusion. Cisplatin was dissolved in 3% saline and adminis-
tered as a 3-h infusion with 24 h hyperhydration. In most patients,
Table 1 Severity of paraesthesias and 'Common Toxicity Criteria' of the NCI
Paraesthesias CTC-Neurosensory
0 = None 0 = No symptoms or signs
1 = Temporary 1 = Mild paraesthesias, loss of
2 = Continuous light deep tendon reflexes
3 = Severe 2 = Moderate paraesthesias,
4 = Unbearable objective sensory loss
3 = Severe paraesthesias, sensory
loss interfering with function
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Table 2 Patient characteristics and tumour type
Number of evaluable patients
Sex
Male/Female
Mean age (years)
(Range)
Tumour type
Colorectal
ACUPa
Breast
Head and neck
Sarcoma
Melanoma
NSCLCb
Miscellaneous
Prior therapy
Cisplatin
Vincristine
Other chemotherapy
55
26/29
53
(21-74)
23
14
5
3
2
2
2
4
27
aAdenocarcinoma of unknown primary. bNon-small-cell lung carcinoma.
docetaxel was given 3 h before cisplatin. In some patients, the
sequence was reversed and docetaxel was given 18 h following
cisplatin administration. Scheduled dose-escalation included
cisplatin doses of 50, 75 and 100 mg m-2 and docetaxel doses of
55, 70, 85 and 100 mg m-2. No other neurotoxic drugs were
applied during the trial or follow-up period.
The severity of neuropathy was assessed by a questionnaire for
neurological symptoms using standardized neurological examina-
tion and measurements of the vibration perception threshold
(VPT) before the start of treatment, after each cycle, at 2 weeks
after the last dose of docetaxel and every 3 months thereafter. The
questionnaire established separately absence (0) or presence (1)
of paraesthesias, numbness, loss of dexterity and unsteadiness
of gait. On sensory examination, position sense, vibration sense,
Table 4 Severity of neuropathy in relation to cumulative dose of docetaxel
and cisplatin
Cisplatin < 200 mg m-2 200-400 mg m-2 > 400 mg m-2
Docetaxel < 200 mg m-2 > 200 mg m-2 > 200 mg m-2
n=20 n=16 n=19
Sensory sum-score 1.1 + 1.2 4.3 ± 2.4 3.5 ± 2.9
increase (mean ± s.d.)a
VPT post - pre ratio 1.2 + 0.7 1.9 ± 0.9 4.3 ± 4.0
(mean ± s.d.)b
Paraesthesiasc
Grade 1 1(1)d 2(2) 5(3)
Grade 2 1(1) 5(4) 3(7)
Grade 3 - 2(3) 3(3)
Grade 4 - 2(2) -(1)
CTC neurosensoryc
Grade 1 3(2) 7(7) 8(10)
Grade 2 -(1) 5(4) 5(3)
Grade 3 - -(1) 1(3)
aDifference between first post-treatment and pretreatment score. bDifference
between first post-treatment and pretreatment score, divided by the
pretreatment score (post - pre ratio). cincidence at first post-treatment
evaluation. dNumbers in paratheses indicate when maximum scores post-
treatment are considered.
Table 3 Neuropathic signs and symptoms at first post-treatment evaluation
No. of Patients (%)
Paraesthesias 24/55 44
Grade 1 8a
Grade 2 9b
Grade 3 5c
Grade 4 2
Pain 3/54d 6
Numbness 17/53 32
Loss of dexterity 14/53 26
Unsteadiness of gait 9/53 17
L'hermitte's sign 7/54 13
Sensory loss 19/46 41
Motor signs 9/54 17
Romberg's sign 2/51 4
Loss of knee jerks 23/55 42
Loss of ankle jerks 29/45 64
aExcluding one patient with pre-existing paraesthesias grade 1. bincluding
one patient with pre-existing paraesthesias grade 1. clncluding one patient
with pre-existing paraesthesias grade 2. dPatients with these signs or
symptoms at pretreatment evaluation or with missing data were excluded.
pin-prick sensation, Romberg's sign, Romberg's sign with heel-
to-toe stand and tendon reflexes of the legs were each scored as
normal (0) orabnormal (1). A sum-score for these signs and symp-
toms was calculated (minimum 0, maximum 11). The severity of
paraesthesias was graded on a 5-point scale (Table I). Sensory loss
was defined as an abnormal test on either position sense, vibration
sense or pin-prick sense. Patients were asked whether they experi-
enced Lhermitte's sign orpain. Distal muscle strength in the lower
extremities was tested. Motor signs were defined as the presence
of objective weakness. The severity of neuropathy was scored
according to the NCI Common Toxicity Criteria (CTC) for
sensory neuropathy (Table 1). VPT was measured at the dorsum of
the second metacarpal bone ofthe left hand with a Vibrameter type
IV (Somedic AB, Stockholm, Sweden) and recorded in micro-
meters (gm) of skin displacement. This vibrameter uses a vibra-
tory frequency of 100 Hz and corrects for pressure-induced
alterations of vibratory amplitude. The method of limits was used
to obtain the mean VPT, and this was repeated three times
(Goldberg et al, 1979). The VPT has been shown to be a reliable
technique to monitor cisplatin neuropathy and shows agood corre-
lation with the sum-score of neuropathic signs and symptoms as
observed previously (Elderson et al, 1989; Gerritsen van der Hoop
et al, 1990b; Hovestadt et al, 1992). It has also been applied to
quantify paclitaxel-induced neuropathy (Gerven et al,1994).
In some patients electrophysiological studies were carried out
before and after treatment. Distal latency and nerve conduction
velocity (NCV) ofthe ulnar (sensory and motor), peroneal (motor)
and sural nerve, compound motor action potential (CMAP) of the
ulnar and peroneal nerve and sensory nerve action potential
(SNAP) of ulnar and sural nerve were determined. A 50%
decrease in CMAP and SNAP amplitude and a 15% decrease of
NCV were considered abnormal.
The first post-treatment evaluation was used as primary end
point for the assessment of neurotoxicity. Cycles of docetaxel and
cisplatin given after the last neurological evaluation, which
occurred in eight patients, were not counted in the analysis and
excluded from the calculation ofthe cumulative dose.
A subdivision was made into three groups, according to cumula-
tive dose ofcisplatin and docetaxel. The mean increase in sum-score
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Figure 1 The mean change (± s.e.) in vibration perception threshold (VPT)
post-treatment in relation to the cumulative dose of docetaxel and cisplatin
(mg m-2). The figures above the horizontal axis indicate the number of
patients evaluated and the mean dose of cisplatin (CP) and docetaxel (DOC)
in each dose subgroup
and the ratio of VPT post-treatment to VPT pretreatment (VPT
post-pre ratio) within groups were calculated. A comparison of the
severity ofneuropathy in relation to cumulative dose was made with
two other prospective trials performed in our institution in the same
period (Hilkens et al, 1994; Hilkens et al, 1996). In these trials,
cisplatin and docetaxel were studied as single chemotherapeutic
agents, and identical methods for measurement ofneuropathy were
applied as described here.
The incidence of neurological signs and symptoms at the first
evaluation after the last cycle was determined. Patients with pre-
existing signs or symptoms were not included in these calcula-
tions. Graded paraesthesias pretreatment were included only if
there was an increase in the grade ofparaesthesias post-treatment.
The change in sensory sum-score and the VPT post-pre ratio were
calculated for each patient. Spearman rank correlations were
calculated to describe the strength of the association between
cumulative doses of cisplatin and docetaxel and the increase in
sensory sum-score and the VPT post-pre ratio. Because of the
skewed distribution of the VPT, the geometric mean was used to
determine the mean of the VPT post-pre ratio. For the sensory
sum-score, the arithmetic mean was calculated.
RESULTS
Sixty-three patients were entered into the trial. Eight of these 63
patients were excluded for assessment of neurotoxicity because of
lack ofpretreatment evaluation.
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Figure 2 The mean change (± s.e.) in sensory sum-score post-treatment in
relation to the cumulative dose of docetaxel and cisplatin (mg m-2). The
figures above the horizontal axis indicate the number of patients evaluated
and the mean dose of cisplatin (CP) and docetaxel (DOC) in each dose
subgroup
Patient characteristics, tumour type and previous chemotherapy
of55 patients evaluable for the present analysis are shown in Table
2. Twenty-seven patients had previously been treated with non-
neurotoxic chemotherapy. One patient had been treated with
vincristine. None of the patients had received prior treatment with
cisplatin. Five patients had diabetes mellitus and five patients
reported alcohol abuse.
Twenty patients received one to two cycles, six patients three to
four cycles, 28 patients five to six cycles and one patient eight
cycles before their last evaluation. The mean dose per cycle of
cisplatin was 74 mg m-2 (range 50-100 mg m-2) and of docetaxel
82 mg m-2 (range 38-100). The mean given cumulative dose of
cisplatin was 297 mg m-2 (range 75-600 mg m-2) and ofdocetaxel
326 mg m-2 (range 75-600 mg m-2). The mean duration of follow-
up after the last cycle was 96 days (range 7-315 days).
Table 3 shows the incidence ofneuropathic signs and symptoms
at the first post-treatment evaluation. Paraesthesias were seen in 24
patients (44%) in both hands and feet (n=18) or in the feet only
(n=6). Three patients suffered from pain in either hands or feet,
which was felt to be secondary to the neuropathy.
Table 4 shows the mean increase in sensory sum-score, the
mean VPT post-pre ratio, the severity of paraesthesias and the
CTC-neurosensory grade at first post-treatment evaluation, classi-
fied by cumulative dose of docetaxel and cisplatin. According to
CTC criteria, 29 patients developed a sensory neuropathy. In the
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Table 5 Comparison of the severity of neuropathy between patients treated with docetaxel alone (Hilkens et al 1996) and patients treated with
docetaxel-cisplatin combination chemotherapy, in relation to the cumulative dose of docetaxel
Docetaxel <300 mg m-2 Docetaxel 300-600 mg m-2
Without cisplatin With cisplatin Without cisplatin With cisplatin
n 14 24 12 31
Cumulative dose of cisplatin (mean ± s.d.) (mg m-2) - 157 ± 65 - 406± 110
Sensory sum-score increase (mean ± s.d.)a 1.5 ± 1.2 1.5 ± 1.7 2.9 ± 2.5 3.9 ± 2.7
VPT post - pre ratio (mean ± s.d.)b 1.4 ± 0.9 1.2 ± 0.7 1.1 ± 0.4 3.3 ± 2.7
Paraesthesiasc
Grade 1 5 1 3 7
Grade 2 1 1 3 8
Grade 3 - 1 - 4
Grade 4 - 1 - 1
CTC neurosensoryc
Grade 1 2 3 7 15
Grade 2 - 2 - 8
Grade 3 - - - 1
aDifference between first post-treatment and pretreatment score. bDifference between first post-treatment and pretreatment score, divided by pretreatment score
(pre-post ratio). cincidence at first post-treatment evaluation.
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Figure 3 The mean change (± s.e.) in vibration perception threshold (VPT)
and sensory sum-score post-treatment in relation to the cumulative dose of
cisplatin (mg m-2). A, Patients treated with docetaxel-cisplatin combination
chemotherapy; 0, patients treated with cisplatin alone (Hilkens et al, 1994)
The figures indicate the number of patients evaluated
group with a cumulative dose of both cisplatin and docetaxel
below 200 mg m-2, 3 out of 20 patients showed a mild sensory
neuropathy (grade 1). Out of 16 patients treated with a cumulative
dose ofdocetaxel above 200 mg m-2 andcisplatin between 200 and
400 mg m-2, 12 patients developed a sensory neuropathy which
was mild in seven patients (grade 1) and moderate in five patients
(grade 2). In the group with cumulative dose of cisplatin above
400 mg m-2 and docetaxel above 200 mg m-2, 14 out of 19 patients
developed a sensory neuropathy, grade 1 in eight, grade 2 in five
and grade 3 in one patient. In four patients, treatment had to be
discontinued because ofneurotoxicity.
Twenty-three patients had two or more post-treatment evalua-
tions. Two ofthese patients developed a mild neuropathy (grade 1)
during follow-up. In four patients, neuropathy further deteriorated
during follow-up; one patient developed a moderate neuropathy
(grade 2) and three patients a severe (grade 3) neuropathy.
In 43 patients, the sequence of administration was docetaxel
before cisplatin and in 12 patients vice versa. There was no differ-
ence in the severity of neurotoxicity as measured with the sensory
sum-scores between these two different regimens.
We found a clear correlation between the increase in VPT and
the increase in sum-score (rs = 0.34, P =0.02) following treatment.
Both the cumulative doses of docetaxel and cisplatin showed a
statistically significant correlation with the increase in sum-score
(rs = 0.44 and 0.39 respectively, P < 0.01) and the change in VPT
(rs = 0.68 and 0.65 respectively, P < 0.001). Figure 1 shows the
VPT post-pre ratio in relation to cumulative doses of docetaxel
and cisplatin. Figure 2 shows the relation of cumulative doses of
these drugs and change in sensory sum-score.
Electrophysiological studies before and after treatment were
carried out in 26 patients. They showed a decrease in SNAP ampli-
tudes in 15 patients, a decrease in CMAP amplitudes in one patient
and both a decrease in SNAP and CMAP amplitudes in four
patients. The NCV studies were unchanged in six patients, most of
whom had been treated with low cumulative doses of both
cisplatin and docetaxel. The cumulative dose in the four patients
with both motor and sensory involvement was similarto the cumu-
lative dose ofpatients with only sensory involvement.
Table 5 shows a comparison of the severity of neuropathy in
relation to cumulative dose of docetaxel between patients in the
combination chemotherapy trial andpatients treated with docetaxel
alone in another prospective trial conducted in our institution
(Hilkens et al, 1996). At low cumulative doses of docetaxel (and
consequently also low doses of cisplatin in the combination
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chemotherapy trial), there is a low incidence of neuropathy in
both trials. When patients with cumulative doses of docetaxel
above 300 mg m-2 are considered, a higher incidence and more
severe neuropathy is found in patients treated with combination
chemotherapy than in patients treated with docetaxel alone.
Figure 3 compares the relative change in VPT and the change in
sensory sum-score in relation to the cumulative dose of cisplatin
between patients from this trial and patients treated with cisplatin
alone (Hilkens et al, 1994). It shows a more severe neuropathy in
the patients treated with the combination chemotherapy regimen,
particularly at higher cumulative doses ofcisplatin.
DISCUSSION
In recent years, docetaxel has appeared to be one ofthe most active
new antineoplastic agents. Peripheral neuropathy is one of the
potentially dose-limiting side-effects. In several phase II trials on
docetaxel, a mild to moderate, mainly sensory, neuropathy was
observed (Aamdal et al, 1994; Bruntsch et al, 1994; Fossella et al,
1994; Francis et al, 1994 a,b; Smyth et al, 1994; Chevallier et al,
1995; Hilkens et al, 1996; New et al, 1996). In a study of 41
patients treated with single-agent docetaxel (100 mg m-2 every 3
weeks, cumulative doses 200-1100 mg m-2) 49% of the patients
developed a usually mild neuropathy (Hilkens et al, 1996). The
neuropathy appeared to be dose dependent and caused severe and
disabling neuropathy in somepatients athigherdose levels. Severe
motor involvement occurred in two ofthese patients.
In trials on combination chemotherapy ofcisplatin with another
taxoid, paclitaxel, a high incidence of neuropathy was found. In a
phase I study of paclitaxel (110-200 mg m-2 per cycle) and
cisplatin (50-75 mg m-2 per cycle) in 44 patients (median number
of cycles, 3; range 1-12), 27% developed a mild to moderate
neuropathy (Rowinsky et al, 1991). The incidence of neuropathy
was disproportionately higher than expected with either paclitaxel
or cisplatin alone at similar single and cumulative doses. In a study
of 32 patients treated with higher doses paclitaxel (135-350 mg
m-2 percycle) and cisplatin (75-100 mg m-2 percycle),75% devel-
oped a neuropathy (Rowinsky et al, 1993). It was suggested that
the neuropathy was mainly due to paclitaxel. The severity of the
neuropathy was related to both the cumulative and single dose of
paclitaxel and the presence ofa pre-existing medical disorder asso-
ciated with neuropathy (diabetes, alcoholism). The neuropathy was
of axonal nature with predominantly sensory signs, although elec-
trophysiological studies established the additional involvement of
motor nerves (Chaudhry et al, 1994).
To date, there are no results of studies on docetaxel-cisplatin
combination chemotherapy regimens. In the present study, we
observed that 53% ofpatients treated with docetaxel and cisplatin,
in a wide range of cumulative doses, developed a mainly sensory
neuropathy. When only patients with cumulative doses of
docetaxel and cisplatin above 200 mg m-2 were considered, 71%
developed a neuropathy. At higher dose levels, some patients
showed moderate or severe neuropathy. Nine of these patients
had motor signs. In 5 out of 26 patients in whom neurophysiolog-
ical studies were performed, motor involvement was found.
Neuropathy was the dose-limiting side-effect in four patients.
We were able to compare the results of this trial with two other
trials performed in our institution in which patients were treated
with either docetaxel or cisplatin as single agent (Hilkens et al,
1994, 1996). As expected, the combination of these two neuro-
toxic agents tends to induce a more severe neuropathy then either
ofthe two drugs alone. However, as these single and combination
chemotherapy schedules were not studied in a comparative trial,
this should be interpreted with caution. As the cumulative dose of
cisplatin and the cumulative dose ofdocetaxel were closely related
in our study, we could not detect which drug accounted for most of
the neuropathy. A synergistic effect of the two drugs cannot be
excluded.
The value of the VPT as a sensitive indicator of neuropathy in
this study is not unequivocal. Several reports have demonstrated
that VPT is a reliable measure ofcisplatin neuropathy (Elderson et
al, 1989; Gerritsen van der Hoop et al, 1990b; Hovestadt et al,
1992). In a previous study, we did not establish a significant rela-
tionship between VPT and the severity of docetaxel-induced
neuropathy, possibly because small fibre functions are compro-
mised in this neuropathy (Hilkens et al, 1996). The change in VPIT,
in this study, can probably be accounted for by cisplatin which
mainly affects large myelinated fibres.
In a phase I study on paclitaxel-cisplatin combination chemo-
therapy, it was suggested that the sequence ofcisplatin administra-
tion before paclitaxel may be related to more profound neutropenia
(Rowinsky et al, 1991). We were unable to detect differences in the
severity ofneurotoxicity in relation to the sequence of administra-
tion of cisplatin and docetaxel. As only 12 patients received
cisplatin before docetaxel, no firm conclusions can be drawn.
In conclusion, the combination chemotherapy of docetaxel and
cisplatin induces a dose-dependent sensory neuropathy. At higher
dose range, neuropathy is encountered in a relatively high propor-
tion of patients. With cumulative doses of both cisplatin and
docetaxel between 200 and 600 mg m-2, one third of the patients
developed a moderate or severe neuropathy. The severity of
neuropathy is higher than with the use of either cisplatin or
docetaxel as a single agent at similar doses. Further study on the
possible attenuating effects ofneuroprotective agents such as WR-
2721 (amifostine) (Mollman et al, 1988; Gandara et al, 1991;
Wadler pt al, 1993), glutathione (Di Re et al, 1993; Cascinu et al,
1995) and nerve growth factor (Apfel et al, 1992; Windebank et al,
1994) is warranted.
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